What is CVE-2022-38351?

CVE-2022-38351 is a high-severity vulnerability in Supremainc Biostar_2, classified under Improper Privilege Management. CVSS score: 8.8/10. Published 2022-09-19.

How severe is CVE-2022-38351?

High severity. CVSS v3 base score is 8.8 out of 10.

Privilege escalation in Supremainc Biostar_2

CVE-2022-38351

A vulnerability in Suprema BioStar (aka Bio Star) 2 v2.8.16 allows attackers to escalate privileges to System Administrator via a crafted PUT request to the update profile page.

Vulnerability class: Privilege Escalation

EPSS: 0.009 (56.5th percentile) — read the EPSS interpretation.

CVSS v3 metric

CVSS v3 base score 8.8 (High). Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H.

Affected products

Supremainc Biostar_2 — versions 2.8.16
N/a — versions n/a

Weakness classification (CWE)

CWE-269 — Improper Privilege Management

References

cve@mitre.org (Exploit, Third Party Advisory, x_refsource_MISC)
cve@mitre.org (Exploit, Third Party Advisory, x_refsource_MISC)

Frequently asked questions

What is CVE-2022-38351?: CVE-2022-38351 is a high-severity vulnerability in Supremainc Biostar_2, classified under Improper Privilege Management. CVSS score: 8.8/10. Published 2022-09-19.
How severe is CVE-2022-38351?: High severity. CVSS v3 base score is 8.8 out of 10.